Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | RGS12 | O14924 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leteprinim SCHEMBL358491 | 0.86 | HPRT1 (0.50) | HPRT1 | |
| Leteprinim SCHEMBL6935182 | 0.85 | HPRT1 (0.49) | HPRT1 | |
| Leteprinim SCHEMBL6931317 | 0.85 | HPRT1 (0.49) | HPRT1 | |
| Leteprinim SCHEMBL194355 | 0.85 | HPRT1 (0.49) | HPRT1 | |
| SCHEMBL5255525 | 0.84 | GAA (0.56) | GAATHRBNPC1RAB9AKMT2A | |
| Leteprinim SCHEMBL194354 | 0.84 | HPRT1 (0.48) | HPRT1KMT2AMEN1 | |
| SCHEMBL27503022 | 0.83 | GAA (0.55) | GAATHRBNPC1RAB9AMAPT | |
| SCHEMBL5250036 | 0.82 | GAA (0.53) | GAATHRBNPC1RAB9AKMT2A | |
| SCHEMBL5252681 | 0.82 | GAA (0.53) | GAATHRBNPC1RAB9AMAPT | |
| SCHEMBL5250419 | 0.81 | GAA (0.54) | GAATHRBNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790344-B1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | claimed |
| EP-1790344-A2 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | Spectrum Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | claimed |
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | claimed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | claimed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-1790344-B1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1294722-B1 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | MERCK EPROVA AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| EP-1790344-A2 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | Spectrum Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | TYMP, TYMS, NGF | GAA 3182/4885THRB 350/4885HPRT1 33/4885 |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | NGF, NUDT1, HPRT1 | GAA 2556/4885THRB 1456/4885HPRT1 3/4885 |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | GAP43, BDNF, APP | GAA 416/4885THRB 3032/4885HPRT1 42/4885 |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | GAA 1184/4885THRB 3527/4885HPRT1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.